[go: up one dir, main page]

ECSP088597A - NOVEDOUS HYDROGEN SULPHATE SALT - Google Patents

NOVEDOUS HYDROGEN SULPHATE SALT

Info

Publication number
ECSP088597A
ECSP088597A EC2008008597A ECSP088597A ECSP088597A EC SP088597 A ECSP088597 A EC SP088597A EC 2008008597 A EC2008008597 A EC 2008008597A EC SP088597 A ECSP088597 A EC SP088597A EC SP088597 A ECSP088597 A EC SP088597A
Authority
EC
Ecuador
Prior art keywords
novedous
hydrogen sulphate
sulphate salt
compound
salt
Prior art date
Application number
EC2008008597A
Other languages
Spanish (es)
Inventor
Richard Anthony Storey
John Demattei
Tsung-Hsun Chuang
Gorkhn Sharma-Singh
Paul Alfred Dickinson
Mohammed Pervez
Christopher John Squire
James Gair Ford
Ronald John Roberts
Original Assignee
Array Biopharma Inc
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38218759&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088597(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc, Astrazeneca Ab filed Critical Array Biopharma Inc
Publication of ECSP088597A publication Critical patent/ECSP088597A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08Radicals containing only hydrogen and carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se relaciona con una sal de sulfato de hidrógeno del Compuesto 1 y solvatos, formas cristalinas y formas amorfas de ella, y con procesos para su preparación. Compuesto 1The present invention relates to a hydrogen sulfate salt of Compound 1 and solvates, crystalline forms and amorphous forms thereof, and processes for its preparation. Compound 1

EC2008008597A 2005-12-21 2008-07-02 NOVEDOUS HYDROGEN SULPHATE SALT ECSP088597A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75278105P 2005-12-21 2005-12-21
PCT/US2006/061895 WO2007076245A2 (en) 2005-12-21 2006-12-12 Novel hydrogen sulfate salt

Publications (1)

Publication Number Publication Date
ECSP088597A true ECSP088597A (en) 2008-08-29

Family

ID=38218759

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008597A ECSP088597A (en) 2005-12-21 2008-07-02 NOVEDOUS HYDROGEN SULPHATE SALT

Country Status (33)

Country Link
US (4) US20100016393A1 (en)
EP (1) EP1968948B1 (en)
JP (1) JP5127723B2 (en)
KR (1) KR101361460B1 (en)
CN (2) CN102329270A (en)
AR (1) AR058696A1 (en)
AU (1) AU2006330759B2 (en)
BR (1) BRPI0620091B1 (en)
CA (1) CA2634149C (en)
CY (2) CY1114303T1 (en)
DK (1) DK1968948T3 (en)
EC (1) ECSP088597A (en)
ES (1) ES2421746T3 (en)
FI (1) FIC20210043I1 (en)
FR (1) FR21C1051I2 (en)
HK (1) HK1124043A1 (en)
HR (1) HRP20130663T1 (en)
HU (1) HUS2100046I1 (en)
IL (1) IL192224A (en)
LT (1) LTC1968948I2 (en)
LU (1) LUC00234I2 (en)
MX (1) MX2008008298A (en)
MY (1) MY157733A (en)
NL (1) NL301139I2 (en)
NZ (1) NZ569792A (en)
PL (1) PL1968948T3 (en)
PT (1) PT1968948E (en)
RS (1) RS52843B (en)
SI (1) SI1968948T1 (en)
TW (1) TWI405756B (en)
UA (1) UA93531C2 (en)
WO (1) WO2007076245A2 (en)
ZA (1) ZA200805705B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275102B1 (en) 2002-03-13 2015-07-29 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
TWI405756B (en) 2005-12-21 2013-08-21 Array Biopharma Inc Novel hydrogen sulphate
CN101896227A (en) * 2007-12-12 2010-11-24 阿斯利康(瑞典)有限公司 Combination comprising an MEK inhibitor and an aurora kinase inhibitor
SA109300195B1 (en) * 2008-03-28 2013-04-20 Astrazeneca Ab A Novel Anti-Cancer Pharmaceutical Composition
WO2011095807A1 (en) 2010-02-07 2011-08-11 Astrazeneca Ab Combinations of mek and hh inhibitors
WO2012145503A1 (en) * 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
KR102080535B1 (en) 2011-11-23 2020-02-24 메디뮨 엘엘씨 Binding molecules specific for her3 and uses thereof
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
HRP20240033T1 (en) 2012-10-19 2024-03-29 Array Biopharma, Inc. Formulation comprising a mek inhibitor
PE20152000A1 (en) 2013-03-06 2016-01-22 Astrazeneca Ab QUINAZOLINE INHIBITORS OF MUTATED FORMS ACTIVATING THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
CN105566327A (en) * 2014-10-09 2016-05-11 江苏恒瑞医药股份有限公司 JAK kinase inhibitor bisulfate crystal type I and preparation method thereof
EP3355923B1 (en) 2015-10-01 2022-02-23 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Histone deacetylase inhibitors for use in the treatment of drug resistant melanoma
RU2727474C2 (en) * 2015-10-06 2020-07-21 Редхилл Байофарма Лтд. Types of combined therapy for cancer treatment
WO2017099591A1 (en) 2015-12-07 2017-06-15 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Treatment of inhibitor resistant braf-mutant cancers
WO2017204626A1 (en) 2016-05-24 2017-11-30 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Combination therapy - combined map2k4/map3k1 and mek/erk inhibition
WO2019096112A1 (en) * 2017-11-14 2019-05-23 深圳市塔吉瑞生物医药有限公司 Substituted benzimidazole compound and composition comprising same
TWI791916B (en) * 2018-10-31 2023-02-11 法商施維雅藥廠 Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same
US12175741B2 (en) * 2021-06-22 2024-12-24 Intrinsic Innovation Llc Systems and methods for a vision guided end effector
WO2023238000A1 (en) * 2022-06-06 2023-12-14 Glenmark Life Sciences Limited Process for preparation of selumetinib and salts thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
PT821671E (en) 1995-04-20 2001-04-30 Pfizer ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES AS MMP AND TNF INHIBITORS
KR20000067904A (en) 1996-07-18 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 Phosphinate Based Inhibitors of Matrix Metalloproteases
EP0922030A1 (en) 1996-08-23 1999-06-16 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
AU5131998A (en) 1997-01-06 1998-08-03 Pfizer Inc. Cyclic sulfone derivatives
ATE248812T1 (en) 1997-02-03 2003-09-15 Pfizer Prod Inc ARYLSULFONYLHYDROXAMIC ACID DERIVATIVES
JP2000507975A (en) 1997-02-07 2000-06-27 ファイザー・インク N-hydroxy-β-sulfonylpropionamide derivatives and their use as matrix metalloproteinase inhibitors
IL131123A0 (en) 1997-02-11 2001-01-28 Pfizer Arylsulfonyl hydroxamic acid derivatives
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
PA8469501A1 (en) 1998-04-10 2000-09-29 Pfizer Prod Inc HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO
PA8469401A1 (en) 1998-04-10 2000-05-24 Pfizer Prod Inc BICYCLE DERIVATIVES OF HYDROXAMIC ACID
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
EP2275102B1 (en) * 2002-03-13 2015-07-29 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US20070027076A1 (en) 2003-09-09 2007-02-01 Fumapham Ag Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
TWI405756B (en) 2005-12-21 2013-08-21 Array Biopharma Inc Novel hydrogen sulphate
SA109300195B1 (en) * 2008-03-28 2013-04-20 Astrazeneca Ab A Novel Anti-Cancer Pharmaceutical Composition

Also Published As

Publication number Publication date
BRPI0620091A2 (en) 2011-11-01
LUC00234I2 (en) 2025-02-03
JP2009521487A (en) 2009-06-04
BRPI0620091B1 (en) 2024-04-30
IL192224A (en) 2014-08-31
CY2021030I2 (en) 2022-03-24
US20120253049A1 (en) 2012-10-04
TW200800915A (en) 2008-01-01
PL1968948T3 (en) 2013-10-31
CN101360718B (en) 2012-01-11
ES2421746T3 (en) 2013-09-05
PT1968948E (en) 2013-07-25
KR20080080200A (en) 2008-09-02
AU2006330759B2 (en) 2012-12-06
LTC1968948I2 (en) 2023-07-10
HK1124043A1 (en) 2009-07-03
CY1114303T1 (en) 2016-08-31
US20140221443A1 (en) 2014-08-07
CN101360718A (en) 2009-02-04
MX2008008298A (en) 2008-09-24
UA93531C2 (en) 2011-02-25
FIC20210043I1 (en) 2021-11-26
AU2006330759A1 (en) 2007-07-05
ZA200805705B (en) 2012-09-26
LTPA2021530I1 (en) 2021-12-27
WO2007076245A3 (en) 2008-01-24
CN102329270A (en) 2012-01-25
SI1968948T1 (en) 2013-08-30
AR058696A1 (en) 2008-02-20
US20100016393A1 (en) 2010-01-21
HUS2100046I1 (en) 2021-11-29
FR21C1051I2 (en) 2023-02-17
WO2007076245A2 (en) 2007-07-05
NZ569792A (en) 2011-01-28
DK1968948T3 (en) 2013-08-26
NL301139I2 (en) 2022-02-22
RS52843B (en) 2013-12-31
CY2021030I1 (en) 2022-03-24
MY157733A (en) 2016-07-15
US9156795B2 (en) 2015-10-13
TWI405756B (en) 2013-08-21
EP1968948A4 (en) 2010-12-15
KR101361460B1 (en) 2014-02-10
FR21C1051I1 (en) 2021-12-24
NL301139I1 (en) 2021-11-03
HRP20130663T1 (en) 2013-08-31
US9562017B2 (en) 2017-02-07
CA2634149C (en) 2013-08-13
EP1968948B1 (en) 2013-05-22
CA2634149A1 (en) 2007-07-05
EP1968948A2 (en) 2008-09-17
IL192224A0 (en) 2009-02-11
JP5127723B2 (en) 2013-01-23
US20160024018A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
ECSP088597A (en) NOVEDOUS HYDROGEN SULPHATE SALT
AR072777A1 (en) SOLID FORMS OF BENDAMUSTINE CHLORHYDRATE
RS51954B (en) Crystalline modifications to pyraclostrobin
MY185130A (en) Romidepsin solid forms and uses thereof
MX2010002836A (en) Bortezomib and process for producing same.
CR8647A (en) CRYSTALINE DELTA-D FORM OF IVABRADINE CHLORHYDRATE, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
ECSP078055A (en) CRYSTALLINE TIGECICLINE SOLID FORMS AND METHODS TO PREPARE THE SAME
AR063347A1 (en) DOCETAXEL CRYSTAL FORMS AND PROCESS FOR PREPARATION
PE20100260A1 (en) SOLID FORMS OF (2S, 3R, 4R, 5S, 6R) -2- (4-CHLORO-3- (4-ETHOXYBENZYL) PHENYL) -6- (METHYLTHI) TETRAHYDRO-2H-PYRANE-3,4,5-TRIOL
MX346822B (en) Prodrugs of 2,4-pyrimidinediamine compounds and their uses.
AR061311A1 (en) PROCESSES TO PREPARE CINACALCET CHLORHYDRATE AND POLYMORPHIC FORMS OF THE SAME
WO2007046881A3 (en) Chemical bridges for enhancing hydrogen storage by spillover and methods for forming the same
TW200716564A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
PT1928783T (en) Treatment of high sulfate containing quicklime
DOP2021000074A (en) NEW SALT OF A BCL-2 INHIBITOR, RELATED CRYSTAL FORM, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
CO6311068A2 (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A SALT, HYDROGEN SULPHATE ACID 6- (4-BROMO-2-CHLORINE-PHENYLAMINE) -7-FLUORO-3-METHYL-3H-BENZOIMIDAZOL-5-CARBOXYLIC AND A MATRIX VEHICLE
BRPI0605917A2 (en) rosuvastatin crystalline intermediate
MX2009003106A (en) Novel crystalline modification of 4- (n-methyl-2-chloro-5-pyridyl methylamino) -2,5-dihydrofuran-2-one.
AR064728A1 (en) FORMS AMORPHES AND CRYSTALS OF RIMONABANT, PROCESSES FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
IL185076A0 (en) Process for the prepartion of enantiomerically pure 1-substituted-3-aminoalcohols
CA113788S (en) Lever
ZA200804753B (en) Crystalline modification of N-ethyl-2,2-dichloro-1-methylcyclopropane-carboxamide-2-(2,6-dichloro-alpha, alpha, alpha-trifluoro-p-tolyl) hydrazone
UY29492A1 (en) ACID HYDROCHLORIDE POLYMORPHIC CRYSTAL 4, - (2- (1S, 2R) -2-HYDROXI-2- (4-HYDROXYPHENYL) -1-METHYLETHYLAMIN) ETOXI) -3-ISOPROPIL-3, -5, -DIMETHYLBYL-CARBOXYL
PE20080692A1 (en) CRYSTALLINE FORMS OF 11ß- (4-ACETYLPHENYL) -20,20,21,21,21-PENTAFLUORO-17-HYDROXI-19-NOR-17ALFA-PREGNA-4,9-DIEN-3-ONA